Dataset Information


Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 (RNA-Seq)

ABSTRACT: LCCC1122 is a window trial in stage I-IV TNBC patients scheduled to undergo definitive surgery (either lumpectomy, mastectomy or surgical resection of oligometastatic disease). Enrolled patients will receive 1.5 -2.0 mg of the MEK1/MEK2 inhibitor GSK1120212 (trametinib; Mekinist®) orally once daily for 7 days (with treatment initiation dependent on surgical schedule) prior to their surgery, with pre- and post- treatment tissue analyzed for kinome response and resistant signatures. A single blood sample will be obtained for determination of plasma GSK1120212 concentration prior to surgery. Of note, the initiation of study treatment is defined by the surgical schedule; there will be no delays in standard treatment for the purposes of this study. Overall design: 28 samples representing 12 patients including pre-treatment needle core biopsies and post-treatment surgical resections Raw data submitted to dbGaP (phs001405.v1.p1; because of patient privacy concerns.

INSTRUMENT(S): Illumina HiSeq 2000 (Homo sapiens)

SUBMITTER: Gary L Johnson  

PROVIDER: GSE107502 | GEO | 2017-11-29



altmetric image


Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving nongenomic adaptive bypass mechanisms. Inhibition of MEK1/2 by trametinib in patients with triple-negative breast cancer (TNBC) induced dramatic transcriptional responses, including upregulation of receptor tyrosine kinases (RTK) comparing tumor samples before and af  ...[more]

Similar Datasets

2017-09-30 | E-MTAB-5978 | ArrayExpress
2016-07-21 | E-GEOD-82329 | ArrayExpress
2009-04-07 | E-GEOD-15578 | ArrayExpress
2014-10-01 | E-GEOD-51831 | ArrayExpress
2009-04-07 | GSE15578 | GEO
2013-04-15 | E-GEOD-37472 | ArrayExpress
2017-05-31 | MSV000081129 | MassIVE
| GSE113513 | GEO
2016-08-08 | E-GEOD-76726 | ArrayExpress
2016-08-08 | E-GEOD-76727 | ArrayExpress